Canopus BioPharma, Inc.

18 articles about Canopus BioPharma, Inc.

• Canopus Biopharma Inc. (OTC: PINK CBIA) dba Blue Heaven Coffee Inc. Announces Inaugural For-Profit Programmatic Advertising Campaign.

  2/20/2024

  Canopus Biopharma Inc. (OTC PINK:CBIA) dba Blue Heaven Coffee Inc. (BHC) proudly announces a monumental leap forward in its retail innovation and expansion efforts.

• Canopus BioPharma, Inc. Announces Positive Results From An In-Vitro Live Ebola Virus Study

  12/19/2014

• Canopus BioPharma, Inc. Announces Results From Compassionate Study In Hepatitis C Patients In China

  7/1/2014

• Major Influenza Pandemic Threat is now Preventable and Treatable with Canopus BioPharma, Inc.'s Aerosol Statin Formulation

  5/12/2009

• Working with U.S. Department of Defense, Canopus BioPharma, Inc. Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300

  11/4/2008

• Canopus BioPharma, Inc. Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine

  11/3/2008

• Canopus BioPharma, Inc. and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic

  8/12/2008

• CB1400, Patented by Canopus BioPharma, Inc., Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck

  6/23/2008

• B1400, Patented by Canopus BioPharma, Inc., Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux)

  6/19/2008

• Canopus BioPharma, Inc. Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement with Wisconsin Alumni Research Foundation (WARF)

  6/18/2008

• Canopus BioPharma, Inc. to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo

  5/15/2008

• Canopus BioPharma, Inc. Engages Pullan Consulting to Commence the Formation of Drug Development and Licensing Partnerships

  5/1/2008

• Canopus BioPharma, Inc. Selected to Present its Drug Candidate for HIV/AIDS Treatment at the Global Summit on AIDS and the Church

  12/3/2007

• New Hepatitis C Antiviral CB5300 Identified by Canopus BioPharma, Inc. Researchers to Enter Clinical Trial Assessment

  10/31/2007

• Canopus BioPharma, Inc. to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

  10/23/2007

• Canopus BioPharma, Inc.'s Novel Antiviral HIV Drug SpirH(TM) Offers New Hope for AIDS Patients Worldwide; Commences Phase II Study and Opens Enrollment for Participation of Clinics Around the World

  10/9/2007

• Canopus BioPharma, Inc.'s StatC Drug Shows Superior Results for Treatment of Avian Flu and Other Influenzas

  8/1/2007

• Drake Holding Corp. Announces Name Change to Canopus BioPharma, Inc. and New Stock Ticker Symbol of CBIA

  7/16/2007